An observational study in Nephrectomy,Kidney Donation, Living Kidney Donor and ESKD, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Active, not recruiting. Open to participants aged 18 Years to 105 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the long-term risks of permanent kidney failure and inpatient dialysis among living kidney donors compared with matched healthy nondonors. This population-based, retrospective cohort study will use linked administrative health care databases from Ontario, Alberta, and British Columbia. Living kidney donors who donated between 1992 and 2025 will be identified and matched 1:10 within each province to a carefully selected population of healthy nondonors based on baseline characteristics. The primary outcome is permanent kidney failure (defined by kidney transplant, chronic dialysis, or eGFR \<15 mL/min/1.73 m²). The secondary outcome is dialysis (inpatient). These results will help support informed consent for potential donors, as well as guidance for transplant clinicians and follow-up care for living kidney donors.
*Background*
Kidney transplantation from living donors is a lifesaving treatment for patients with kidney failure. To support informed consent and guide long-term health care, living kidney donors need accurate information about their future kidney health. Although studies have reported a higher risk of kidney failure in living donors compared with nondonors, the absolute risk remains low, with fewer than 0.5% of donors developing kidney failure within 15 years of donation. However, the quality of this evidence has been rated as poor, and it remains unclear whether the observed excess risk is attributable to donor nephrectomy itself, underlying hereditary factors, or differences in outcome ascertainment. For example, living donors are more likely than nondonors to have a family history of kidney failure or hypertension and typically undergo more frequent follow-up assessments, creating greater opportunities to detect adverse kidney outcomes.
*Study Setting and Data Sources*
In Ontario, the study will use linked administrative health databases, including Trillium Gift of Life Network (TGLN), the Registered Persons Database (RPDB), the Ontario Health Insurance Plan (OHIP) Claims Database, and datasets from the Canadian Institute for Health Information (CIHI), including the Discharge Abstract Database (CIHI-DAD), National Ambulatory Care Reporting System (NACRS), and Same Day Surgery (SDS) database. As most hospital discharge and physician billing data are available beginning in 1991, July 1, 1992, will mark the start of the accrual period. Living kidney donors will be identified primarily through TGLN, with CIHI-DAD used to supplement donor identification during periods when TGLN data are incomplete.
The Ontario portion of this study will be conducted at ICES (ices.on.ca), an independent, non-profit research organization designated as a prescribed entity under Ontario's health privacy legislation. This designation permits ICES to collect, use, and analyze health and demographic information without individual consent for the purposes of health system evaluation and improvement. The use of data for this project is authorized under Section 45 of Personal Health Information Protection Act (PHIPA) and does not require approval from a Research Ethics Board.
Comparable administrative data sources will be used in Alberta and British Columbia to enable harmonized analyses across provinces. All ethics approvals have been obtained in these provinces. In Alberta, data will be accessed through the Alberta Kidney Disease Network (AKDN) and Alberta Health Services (AHS), contingent on analyst assignment and data availability. Living kidney donors will be identified using CIHI-DAD, with demographic and vital statistics obtained from the Alberta Provincial Registry and Vital Statistics databases. Information on hospitalizations, diagnoses, and health care encounters will be obtained from CIHI-DAD, NACRS, and the Alberta Practitioner Claims database.
In British Columbia, data will be accessed through Population Data BC (PopDataBC) and the Healthcare Data Platform BC (HDPBC). Living kidney donors will be identified using data from BC Transplant and the Patient Records and Outcome Management Information System (PROMIS), accessed through BC Renal; if unavailable, CIHI-DAD will be used. Demographic and vital statistics will be obtained from PopDataBC's Consolidation File/Central Demographics database, and health care utilization data will be sourced from CIHI-DAD, CIHI-NACRS, and PopDataBC's Medical Services Plan database. Ethics approval has been obtained from their respective institutions in Alberta and British Columbia.
This retrospective cohort study will use existing administrative health care data. Consistent with best practices for observational research, the study objectives, design, and statistical analysis plan will be publicly registered on ClinicalTrials.gov prior to the initiation of outcome analyses.
*Study Population*
Living kidney donors will be accrued between July 1, 1992, and March 31, 2025, subject to data availability. The date of the donation nephrectomy will serve as the cohort entry date. Before nephrectomy, living donors undergo rigorous health screening. A similarly healthy segment of the general population will be selected using epidemiological techniques of restriction and matching. A random cohort entry date (simulated nephrectomy date) will be assigned to all persons who were residents of the province, according to the distribution of cohort entry dates among donors (July 1, 1992, to March 31, 2025). After a simulated nephrectomy date is assigned, the sample of nondonors will then be restricted to nondonors without medical conditions that would preclude donation. Additionally, only those who have visited a family physician at least once in the prior 2 years will be included to ensure health care access. Follow-up will commence at cohort entry and will be censored at the earliest of the first occurrence of the outcome of interest, death, emigration from the province, or the end of the observation period (March 31, 2026).
*Baseline Characteristics and Matching*
Donors and nondonors will be matched 1:10 on baseline characteristics including cohort entry date (date of donation/simulated donation), sex, age, residential status (rural vs. urban), and income quintile (if urban). Baseline characteristics will be summarized using descriptive statistics. Continuous variables will be reported as mean (standard deviation) or median (interquartile range [IQR]), as appropriate, and categorical variables will be reported as counts (percentages). Given the anticipated large cohort size and the limitations of hypothesis testing in this context, differences between donors and nondonors at cohort entry will be assessed before and after matching using standardized mean differences (SMDs), with values greater than 0.10 indicating meaningful imbalance. Donor-specific characteristics will also be described where data are available, including pre-nephrectomy kidney function and donor-recipient relationship.
*Outcomes*
The primary outcome will be permanent kidney failure, defined as a composite of receipt of a kidney transplant, chronic dialysis, or a sustained estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m². Chronic dialysis will be defined as two dialysis-related codes occurring at least 90 days apart but no more than 150 days apart. Sustained eGFR \<15 mL/min/1.73 m² will be defined by two measurements below this threshold separated by at least 90 days but no more than 365 days and will be calculated using the 2021 CKD-EPI creatinine equation without race. A secondary outcome will be receipt of dialysis at least once during a hospital admission.
*Statistical Analysis*
The primary analysis will examine the association between living kidney donation and the risk of permanent kidney failure. Only the first qualifying event will be considered. Hazard ratios (HRs) and 95% confidence intervals (CIs) will be estimated using Cox proportional hazards regression with robust variance estimation to account for correlation within matched sets.
Prespecified subgroup analyses will be performed to evaluate potential effect modification in the association between living kidney donation and permanent kidney failure and inpatient dialysis. Analyses will be stratified by age at cohort entry (\<55 vs ≥55 years), sex (male vs female), and cohort entry period (1992-2001, 2002-2012, and 2013-2025). For each subgroup, hazard ratios and 95% confidence intervals will be estimated using Cox proportional hazards regression with robust variance estimation, consistent with the primary analysis. Risk factor analyses will evaluate the association between baseline characteristics and the primary outcome, including age (modelled per 5-year increase), sex (male vs female), rurality (urban vs rural residence), neighbourhood income quintile (modelled per quintile), and cohort entry year (modelled per 1-year increase).
To enhance statistical power and generalizability, outcome estimates for the primary outcome from Ontario, Alberta, and British Columbia will be combined using a privacy-preserving Cox regression approach for multisite studies in which individual-level data cannot be shared. The secondary outcome will be combined across provinces based on data availability. The privacy-preserving approach requires a single transfer of summary-level outputs from each province and produces estimates equivalent to those obtained from pooled individual-level data. Province-specific baseline hazards will be assumed, with confounding control (e.g., matching) performed independently within each province. Summary-level risk-set tables will be securely transferred to a coordinating site to estimate combined hazard or risk ratios with corresponding 95% confidence intervals. In accordance with privacy requirements, all cell sizes of five or fewer will be suppressed (reported as ≤5) in publications, and all study personnel will comply with applicable data confidentiality and data use agreements.
*Additional Analyses*
A subgroup analysis will be performed to evaluate whether the association between living kidney donation and study outcomes differs according to the presence of a first-degree relative with kidney disease. The primary analysis will be repeated among donors and matched nondonors stratified by the presence or absence of a first-degree relative. Specifically, outcomes will be compared for donors with a genetic relationship to the recipient versus their matched nondonor controls, and separately for donors without a genetic relationship to the recipient versus their matched nondonor controls. Analyses will be conducted for the primary and secondary outcomes. We will use data available to determine first-degree relative versus not a first-degree relative.
Among living kidney donors only, a secondary analysis will examine whether having a first-degree relative with kidney disease is associated with the primary and secondary outcomes. Exposure will be defined as having a first-degree relative with kidney disease, as determined by the donor-recipient relationship, with donors without a first-degree relative with kidney disease serving as the reference group. A propensity score for having a first-degree relative with kidney disease will be estimated using logistic regression with baseline covariates including age, sex, income quintile, rurality (urban vs. rural), and cohort entry year. Inverse probability of treatment weighting (IPTW) will then be applied using weights estimating the average treatment effect in the treated (ATT). Weights exceeding the 99th percentile or below the 1st percentile will be truncated to those percentile values. Baseline characteristics before and after weighting will be reported. Covariate balance between groups will be assessed using standardized differences, with values > 0.10 considered indicative of meaningful imbalance. The number of events, number at risk, proportion of participants with events, event rates per 1,000 person-years, and hazard ratios will be reported between the weighted groups.
Follow-up kidney function testing will also be described. Among donors and nondonors, the number and proportion of participants with serum creatinine testing and the median (IQR) and mean (SD) number of tests during follow-up, overall and by year of follow-up, will be reported. Among donors only, the number at risk, the number of donors with at least one serum creatinine measurement in each year of follow-up, the total number of serum creatinine tests, the median (IQR) number of tests, and the distribution of donors across eGFR categories ≥60, 15 to \<60, and \<15 mL/min/1.73 m²) will be reported annually.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
This study's planned enrollment of 55,000 is above the median of 180 across 293 observational studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 332 studies on the registry; 137 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Living kidney donors matched to nondonors from the general population with similar indicators of baseline health.
*Donors* Inclusion Criteria: Living kidney donors who underwent donor nephrectomy in Ontario, Alberta, and British Columbia, Canada, between July 1, 1992, and March 31, 2025, are eligible to enter the study.
Exclusion Criteria:
*Non-donors* Inclusion criteria: Before nephrectomy, living donors undergo rigorous health screening. A similarly healthy segment of the general population will be selected using restriction and matching. A random cohort entry date (simulated nephrectomy date) will be assigned to all persons who were residents of the province, according to the distribution of cohort entry dates among donors (July 1, 1992, to March 31, 2025).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Living kidney donors who had a donor nephrectomy between July 1, 1992, and March 31, 2025, at transplant centres in the provinces of Ontario, Alberta, and British Columbia. Each nephrectomy date will serve as the cohort entry date.
Procedure: Living kidney donation
A similarly healthy segment of the general provincial population selected using restriction and matching to emulate the health criteria required to be met for living kidney donation. A cohort entry date (simulated nephrectomy date) will be randomly assigned to all residents in the province, according to the distribution of cohort entry dates in the donor cohort (between July 1, 1992 and March 31, 2025).
Nephrectomy for living kidney donation
Also known as: Donor nephrectomy
Permanent kidney failure
Defined as a composite of receipt of a kidney transplant, chronic dialysis, or a sustained estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m². Chronic dialysis will be defined as two dialysis-related codes occurring at least 90 days apart but no more than 150 days apart. Sustained eGFR \<15 mL/min/1.73 m² will be defined by two measurements below this threshold separated by at least 90 days but no more than 365 days and will be calculated using the 2021 CKD-EPI creatinine equation without race.
Time frame: Donors and matched nondonors will enter the cohort between July 1, 1992, and March 31, 2025, and will be followed until study outcome (first event), death, emigration from the province, or the end of the observation period (March 31, 2026).
Inpatient dialysis
A receipt of dialysis at least once during a hospital admission.
Time frame: Donors and matched nondonors will enter the cohort between July 1, 1992, and March 31, 2025, and will be followed until study outcome (first event), death, emigration from the province, or the end of the observation period (March 31, 2026).
No study locations are listed for this record.
Plan to share: No — The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das@ices.on.ca). Similarly, the Alberta and British Columbia datasets are held securely by their respective data stewards, and access is governed by provincial privacy legislation and data sharing agreements. The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.
Ran from Jul 1992 to primary completion in Mar 2025, 392 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's →